Beta Drugs, a vertically integrated oncology-focused formulations company in Himachal Pradesh, has raised primary capital worth ₹117 crore from HealthQuad Fund II, and other investors including a Singapore-based investment fund and a private wealth management firm for a minority stake in the Company.
Rahul Batra, Chairman & Managing Director, Beta Drugs said, “We are thrilled to welcome HealthQuad as partners in Beta Drugs. Their investment and expertise will play a pivotal role in accelerating our growth journey, as we strive to position ourselves among the top five oncology companies in India over the next five years. By leveraging HealthQuad’s global network and deep knowledge of the pharmaceutical industry, we are confident in our ability to drive innovation, expand our reach, and enhance patient care.”
Ajay Mahipal, Partner, HealthQuad Capital, said, “We are excited to partner with Beta Drugs in this pivotal phase of their growth journey. Beta Drugs, with its strong manufacturing and R&D capabilities, is poised to improve affordability in the middle- and lower-income segment, and accessibility in tier II and tier III cities in the country. We believe in the transformative potential of their new product launches, expanding export markets, and experienced management team, all of which position the company for substantial growth and value creation.”
Founded in 2005, Beta Drugs offers a broad product portfolio across all major oncology segments, including chemotherapy, targeted, hormonal and supportive therapy.
Notably, Beta Drugs was also the first company in India to introduce oncology drugs in suspension form. As one of the few vertically integrated manufacturers in the country, the company has established a robust position within the country and has also expanded its footprint to over 46 countries, holding accreditations from regulatory bodies such as ANVISA Brazil, INVIMA, PICS, and EAEU.
